Meet the founder Global Health Exhibition — Riyadh, KSA 26–29 October 2026 Book a time

Go-to-Market Evolution

Your market, under your name — built with you, not for you.

Whether this is your first entry into Egypt and the Gulf, or a re-entry to unlock growth that has stopped, we take the whole journey with you: opportunity, registration, channel, team and execution.

Where you are

Two starting points. The same journey.

Almost every conversation begins as one of these. The work differs at the start and converges quickly.

First Entry

“We have the product. We don’t have the market.”

For a portfolio coming into Egypt, Saudi Arabia or the Gulf for the first time. Opportunity assessment and sizing, entry model, regulatory pathway and registration, channel selection, pricing position, and the launch plan behind them — followed by the team that carries it.

Expand into Establish

Re-Entry

“We are here already, and growth has stopped.”

For a presence that is underperforming and cannot easily be changed. Honest assessment of the current channel against evidence, a market-access structure that restores your options, channel redesign or replacement, and the governance to hold the new arrangement to account.

Expand, then rebuild

The constraint

Egypt is growing. What limits most MedTech companies here isn’t demand — it’s the structure they entered with.

Most entry models hand the product licence to the distributor. It rarely feels like a constraint on day one — it becomes one the moment growth depends on changing something.

What that costs you

Performance slips and there is no practical way to move. Re-registering under a new partner takes time and stalls market penetration while it runs, so renegotiation only runs one way. Market feedback arrives filtered through the party it reflects on, forecasts drift from what is happening in hospitals, and the regional plan gets written against a channel you cannot change.

How we work instead

EXVERINA structures market access so the registration no longer sits with the party selling your products. We are independent by default: paid for the work, never on your sales. Commercial representation happens only where you ask for it and only as a separate, explicitly agreed engagement. Keep your distributor, replace one, split the territory or go direct — the decision stays yours, and it stays reversible.

  • Independent by defaultGo-to-Market engagements are paid for the work, not on your sales.*Except for certain product categories, agreed separately with you.
  • Licence under your authorised representativeRegistration is structured so marketing, promotion and channel management authorisation stays with you, under the model we agree together as the best route to adoption of your technology.
  • A straight readIf the market or the timing does not support entry, that is what you will hear.

Markets

Three markets, three different problems and opportunities.

Egypt, Saudi Arabia and the Gulf are usually treated as one regional line in a plan. They behave nothing alike, and the stage of EX³ that matters differs in each.

MarketWhat it takesWhere EX³ starts
Egypt Our home market. Registration, channel structure and the commercial plan are decided here, and this is where control of the licence changes what is possible. Expand-led
Saudi Arabia The high-value growth market, and the one that rewards being properly set up. Entity structure, regional headquarters requirements and the SFDA pathway set the commercial ceiling. Product localisation lifts it: meeting local content requirements turns a supplier into a preferred one, and that is where the real growth in the Kingdom now sits. Establish-led, with Enable in parallel
Rest of the Gulf The UAE, Kuwait, Qatar, Bahrain and Oman. Where teams and partners are based, where capability building pays back fastest, and where one commercial structure can cover several smaller tender-driven markets at once. Expand and Enable together

The method

EX³ applied to your market

The same three stages, run alongside you rather than handed to you.

Expand

Find the opportunity and take control of the route to it.

  • Market and opportunity assessment
  • Segment and account mapping
  • Go-to-market and channel model
  • Pricing and tender position
  • Channel assessment or selection
  • Competitive and customer intelligence

Establish

Put the structure in place that makes growth repeatable.

  • Registration and regulatory pathway
  • Scientific office and entity setup
  • Compliance and operational readiness
  • Localisation and local content in Saudi Arabia
  • Contracts and channel governance
  • Reference accounts secured

Enable

Hand over a team that can run without us.

  • Recruitment of the local team
  • Commercial and clinical training
  • Operating rhythm and pipeline discipline
  • Leadership and capability building
  • Stakeholder and KOL management
  • Performance reporting you can act on

How it runs

A journey, not a deliverable.

Every engagement is shaped around the portfolio and the market. This is the shape it usually takes.

  1. Read the marketOpportunity, competition, pricing reality and the honest size of the prize — before anything is committed.
  2. Agree the modelEntry route, channel structure, registration approach and the commercial plan that follows from them.
  3. Build the structureRegistration, scientific office, compliance and the contracts that keep your options open.
  4. Go to marketLaunch, reference accounts, tender positioning and the first proof that the plan works.
  5. Build the teamRecruitment, training and the operating rhythm that turns activity into a pipeline.
  6. Hand overYou run it. We stay as close or as far as you want from that point.

Tell us where growth is stuck.

A short note about the product line and the market is enough to start. You will get a straight read on what is realistic.

Start a conversation